Pierre Fabre Laboratories gains exclusive antimalarial Eurartesim license
Eurartesim successfully met the recommendations of the World Health Organization (WHO), proving that this Artemisinin-based Combination Therapy (ACT) will be used in the first lines within endemic areas. The drug gained marketing authorization in 2012 within Europe.
“We are very happy to announce this important agreement for the distribution of Eurartesim, the drug developed from our research activities, in the field of antimalarial treatment,” Raffele Sanguigni, Sigma-Tau general manager, said. “The distribution territory will cover nearly all of Africa. We are committed to ensuring its registration and distribution in those countries where malaria is endemic.”
Now Pierre Fabre is allowed to administer, distribute, register and promote the drug to people within 32 countries in Africa, including Guinea, Senegal, Ivory Coast, Mali, Burkina Faso, Togo, Niger, Madagascar, Congo, Benin, Chad, RDC, Cameroon, Gabon, Sierra Leone, Mauritania, Nigeria, Burundi, Kenya, Ghana, Uganda, Tanzania, Ethiopia, Angola, Liberia, Malawi, Zambia, Mozambique, Botswana, Namibia, Zimbabwe and Swaziland.
"Eurartesim is a drug with proven efficacy in combating malaria, a major health scourge in Africa,” Frédéric Duchesne, president of Pierre Fabre Pharmaceuticals, said. “It thereby complements our portfolio of medicines and health products already widely distributed on the African continent where Pierre Fabre Group ranks among the top 10 pharmaceutical companies in terms of turnover. Our commitment in Africa is long-standing, and strengthening it is a key priority in our strategic plan Trajectoire 2018.”